ANN ARBOR, Mich., Oct. 8 /PRNewswire/ -- Ann Arbor-based Genetics Squared, Inc., announced today that it has formed a scientific advisory board to provide Genetics Squared management with expert advice on future scientific direction of the industry as well as scientific and medical opportunities for the company. Genetics Squared is an emerging biotechnology company that uses its patented evolutionary drug development(TM) software and methods to rescue promising but struggling compounds from clinical and market failure.
The Company named Dr. Richard Cote, professor of pathology and urology at the University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, as chairman of the scientific advisory board. Along with Genetics Squared management, Dr. Cote will recruit additional members to the advisory board, particularly from the field of clinical oncology. Dr. Cote has been collaborating with Genetics Squared to identify the molecular signatures of bladder cancer progression.
"We have found Genetics Squared's SKGP technology and process powerful," said Dr. Cote. "It will be useful in moving towards our goals of patient- specific versus population-based treatment."
Dr. Cote serves as the director of the Genitourinary Cancer Program and is head of the laboratory for immuno and molecular pathology. His research focuses on the molecular biology of tumorigenesis and cancer progression. Dr. Cote's work has led to a number of international clinical trials in the areas of occult metastases in breast and lung cancer as well as molecular determinants of progression and response in bladder cancer. He has served as a consultant to the National Cancer Institute. Dr. Cote received his medical degree at the University of Chicago Pritzker School of Medicine and completed his residency in pathology at Cornell University Medical Center/New York Hospital.
"Genetics Squared is thrilled to have someone with Dr. Cote's credentials leading its scientific advisory board," said John Freshley, president and CEO. "Dr. Cote has a distinguished track record in academia, and as a founder of Impath, he is very familiar with needs and goals of an emerging company."
In addition to Dr. Cote, Genetics Squared's advisory board includes:
David W. Fry Ph.D. -- Dr. Fry is a consultant and lecturer on drug discovery and targeted therapeutics in cancer. In addition to his role on the advisory board, Dr. Fry serves Genetics Squared as a consultant on a permanent part-time basis. Formerly, he was a senior research fellow, department of cancer pharmacology, Pfizer Global Research and Development, where he earned international recognition for his contributions to the science of oncology drug discovery. Prior to that, he held various research fellowships with Parke-Davis Pharmaceutical Research. He belongs to the American Association for Cancer Research and the American Society for Biochemistry and Molecular Biology. Dr. Fry holds a Ph.D. in biochemistry from Ohio State University.
Phillip L.C. Banks -- Banks is director, biostatistical research and consulting for Statprobe. He provides biostatistical oversight on projects including statistical analysis plan development, writing of clinical protocols, interpretation of clinical data for reports and publications, and senior review of technical documents. Banks is an M.S. biostatistician with 21 years of pharmaceutical and biotechnology industry experience. His major technical expertise exists in study design, survival analysis, nonparametric methods, and sequential testing/estimation particularly in cancer clinical trials. He holds an M.S. in preventive medicine from Ohio State University.
About Genetics Squared
Founded in 2002, Genetics Squared is an emerging biotechnology company focused on delivering the promise of personalized medicine. Using its patented evolutionary drug development(TM) technology and methods, Genetics Squared is able to "rescue" promising, but struggling compounds from clinical and market failure. The company's novel analytical approach discovers pharmacogenomic profiles of therapeutic responders and non-responders or those most likely to experience serious adverse events. This allows the company and its service clients to target these promising therapies at the patients most likely to benefit. For more information, please visit http://www.genetics2.com/ .
Genetics Squared, Inc.